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Abstract
Successful vaccine development against HIV will likely require the induction of strong, long-lasting humoral and cellular
immune responses in both the systemic and mucosal compartments. Based on the known immunological linkage between
the upper-respiratory and urogenital tracts, we explored the potential of nasal adjuvants to boost immunization for the
induction of vaginal and systemic immune responses to gp140. Mice were immunized intranasally with HIV gp140 together
with micellar and emulsion formulations of a synthetic TLR4 agonist, Glucopyranosyl Lipid Adjuvant (GLA) and responses
were compared to R848, a TLR7/8 agonist, or chitosan, a non TLR adjuvant. GLA and chitosan but not R848 greatly
enhanced serum immunoglobulin levels when compared to antigen alone. Both GLA and chitosan induced high IgG and
IgA titers in nasal and vaginal lavage and feces. The high IgA and IgG titers in vaginal lavage were associated with high
numbers of gp140-specific antibody secreting cells in the genital tract. Whilst both GLA and chitosan induced T cell
responses to immunization, GLA induced a stronger Th17 response and chitosan induced a more Th2 skewed response. Our
results show that GLA is a highly potent intranasal adjuvant greatly enhancing humoral and cellular immune responses,
both systemically and mucosally.
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Introduction
There is a general consensus that to prevent HIV infection an
efficacious vaccine will need to induce both humoral and cellular
immune responses. The generation of broadly neutralizing
antibodies has been a goal of HIV vaccine research, but to date,
efforts have largely been unsuccessful in both animals and humans
inducing, at best, short-lived humoral responses that provide
modest neutralization, most often limited to homologous virus and
easy-to-neutralize (Tier 1) isolates [1–3]. The lack of broadly
neutralizing antibodies following HIV vaccine trials is unsurpris-
ing, a number of broadly neutralizing antibodies have been
isolated from humans [4], but these only develop in a very low
proportion of them (.1%) after a period of many months to years
[5]. Translating these findings into the development of immuno-
gens capable of inducing similar responses in seronegative
individuals poses a significant challenge where the timescale of
discovery is uncertain [6,7]. Nevertheless other effector functions
such as viral aggregation (particularly by dimeric IgA), mucus
trapping, inhibition of transcytosis, antibody dependent cellular
cytotoxicity (ADCC), and Fc-mediated inhibition of infection may
all enhance protection by antibody [8]. It is of note that V1/V2
binding antibodies and not neutralization were a correlate of
protection in the RV144 trial [9] showing a modest protective
efficacy, suggesting non-neutralizing antibodies may have had
some impact on HIV acquisition.
Responses against HIV are predicted to be most effective at
mucosal portals of HIV entry, since mucosal cellular responses
may be required to control or eliminate the initial foci of infected
cells. Previous human vaccine efficacy trials have focused on
parenterally administered candidates which can induce response
systemically and at mucosal sites. Systemic vaccination can induce
mucosal immune responses, for example the HPV vaccine [10].
But mucosal immunization may alter the type of the mucosal
immune response, in particular boosting IgA responses [11]. Our
initial studies tested the efficacy of the vagina, the main site of
infection, as an immunization site, but we observed that it was
a poor site for the priming of antibody responses [12,13]. Little is
known about the induction of male genital tract immunity by
parenteral or mucosal vaccines. Intranasal immunization may be
a preferable option, due to the apparent immunological linkage
between the upper-respiratory and urogenital tracts [14], the
requirement for lower amounts of antigen than direct vaginal
immunization and independence of the stage of the reproductive
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cycle [15] or patient gender. However, the impact of intranasal
immunization on colorectal responses has been less well studies.
Despite the apparent advantages of intranasal immunization,
there are no safe and effective mucosal adjuvants approved for
human use. Indeed, widely accepted adjuvants such as Alum salts
and MF59 used for systemic immunization are unsuitable for
intranasal use due to their intrinsic generalized pro-inflammatory
properties [16]. Bacterial toxins such as cholera toxin (CT) and
heat-labile enterotoxin of Escherichia coli (LT) have been extensively
studied as nasal adjuvants in mice [17] and humans [18], but may
be of limited use in humans due to their potential neuronal
binding and association with the induction of Bell’s palsy or facial
nerve paralysis [19,20]. Therefore, the identification of safe and
effective intranasal adjuvants remains a critical gap for de-
velopment of nasal vaccine strategies designed to induce urogenital
antibody responses.
Formulated Toll-Like Receptor (TLR) agonists provide potent
adjuvant candidates for mucosal use [21]. TLR4 agonists
represent attractive candidates due to their good safety record
associated with use in a number of parenteral adjuvants [22].
Triggering of TLR4 on the cell surface of antigen presenting cells
is an important gateway for induction of innate and adaptive
immune responses [23]. LPS, the prototype TLR4 ligand, is
unsuitable for clinical use due to its high pyrogenicity, thus,
modified products structurally related to LPS but devoid of high
pyrogenicity and maintaining strong immunopotentiating char-
acteristics have been developed. MPLA (monophosphoryl lipid A),
a non-toxic derivative of LPS was the first TLR ligand and
biological adjuvant approved for human use for its safety and
effectiveness [24]. MPL is derived from acid hydrolysis of bacterial
endotoxin, does not have the pyrogenic and toxic effects of LPS
[25] and has been used for a number of human vaccines [26]. New
generations of TLR4 agonists are being developed that are more
receptor specific, possess less side effects but maintain or increase
the adjuvant activity, including synthetic lipid A-like molecules
such as glucopyranosyl lipid adjuvant (GLA) [27,28] and
aminoalkyl glucosaminide 4-phosphates (AGP) [29]. In contrast
to MPLA, both AGP and GLA can be synthesized as highly pure,
single chemical entities, and can be chemically modified in
a defined manner to enhance their biological activity.
The aim of this work was to assess the potential of a micellar
formulation of a synthetic TLR4 ligand, GLA-AF, to enhance
systemic and mucosal immune responses to the gp140 HIV Ag
after intranasal (i.n.) immunization. We compare the effects of
a synthetic TLR4 ligand (GLA) to promote humoral immune
responses to gp140 to that of a TLR7/8 synthetic ligand agonist
Resiquimod (R848), and the non-TLR adjuvant chitosan. Our
data indicate that GLA induced potent humoral and cellular
immune responses to i.n. immunization with gp140 in local and
distant mucosas, as well as in the systemic compartment. These
data suggest that GLA-AF may represent an important new
adjuvant for mucosally delivered HIV vaccines.
Materials and Methods
Animals
Female BALB/c or C57BL/6 mice, 6–8 week old, were
obtained from Harlan Olac Ltd (Landue, UK), Charles River
(Wilmington, MA) or Jackson Laboratories (Bar Harbor, ME). All
procedures were performed in accordance with the United
Kingdom’s Home Office standards under the Animals Scientific
Procedures Act, 1986, and approved by the School’s Ethical
Review Committee or IDRI Institutional Animal Care and Use
Committee (IACUC).
Antigen and Adjuvants
A clade C HIV-1 envelope clone p97CN54 was originally
isolated from a Chinese patient [30] and was made available by H.
Wolf and R. Wagner, University of Regensburg, Germany.
Trimeric gp140 (gp120 plus the external domain (ED) of gp140),
designated CN54 gp140, was produced as a recombinant product
in CHO cells and manufactured to GMP specification by Polymun
Scientific, Vienna, Austria.
The micellar formulation of GLA has been denoted previously
as IDRI-AQ001 [31] and the emulsion as EM005 and are more
generally denoted as GLA-AF and GLA-SE respectively. Bi-
ological and physicochemical characterization of GLA has been
published previously [28]. R848 was used as an aqueous
formulation and has been previously denoted as IDRI-RM002.
Both adjuvant systems were obtained from the Infectious Diseases
Research Institute (IDRI, Seattle, U.S.). Protasan UP G 213 (FMC
BioPolymer, AS, Novamatrix, Norway) is a chitosan glutamate
where 75–90 percent of the acetyl groups are deacetylated. The
cationic polymer is a high molecular weight (200,000–600,000 g/
mol) chitosan with very low levels of endotoxin and manufactured
under GMP, it contains #100 EU/g endotoxin.
Immunization Protocol
Mice were immunized 2–3 times with 3 weeks interval, with 10–
20 mg gp140, with or without adjuvants: 10 mg GLA-AF and
R848, and 100 mg chitosan in a maximum volume of 25 ml. The
formulation was gently dispensed in the animal’s nostrils after
isofluorane (BALB/c) or ketamine-induced anesthesia (C57BL/6).
Intramuscular immunizations were delivered in two 50 ml
volumes, one per leg.
Sample and Tissue Collection
Serum and mucosal samples were obtained at pre-immuniza-
tion and 21 days after each immunization as described previously
[32]. Nasal washes were obtained at the end of the experiment.
Splenocytes were isolated by mechanical dissociation through
sterile nylon mesh, followed by red blood cell lysis. Cells were
always kept on ice unless specified otherwise.
The mouse genital tract, including vagina, uterus, oviducts, and
ovaries were dissected from the animal, and placed in cold CM
(RPMI-1640 supplemented with 10% fetal bovine serum (FBS),
2 mM glutamine, 10 mM HEPES, 100 IU/ml penicillin, 100 mg/
ml streptomycin, and 10 mg/ml gentamycin). The tissue was finely
cut with a scalpel, washed with CM and digested at 37uC for 1 h
on a shaker with 5 ml of serum-free RPMI-1640 medium that
contained 2 mg Collagenase Dispase and 0.1 mg/ml DNaseI
(Roche Diagnostics). The digested tissue was spun and the cell
pellet washed twice in CM. The lymphoid cell population was
separated from the stromal cells by density gradient centrifugation
(Lympholyte, Cedarlane Laboratories).
ELISA
HIV gp140 specific antibody ELISA were performed as
described previously [32]. In brief, plates were coated overnight
with 5 mg/ml gp140 in PBS. Serially diluted samples were
incubated for 1 hr at 37uC prior to detection with Ig isotype
specific secondary antibody. To increase IgA sensitivity biotin-
Streptavidin HRP amplification step was used. Plates were
developed with TMB (Pierce) prior to quenching with H2SO4
and reading at 450 nm. A mix of pre-immune samples was run in
6 replicates per plate, and the cut-off for titer calculation
calculated (after subtracting the blank) as the mean of these 6
values plus 3 SD, except for that of feces where 5 SD were used.
GLA as a Mucosal Adjuvant for an HIV Antigen
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41144
ELISPOT
Cells from genital tract, bone marrow and spleen were assessed
for the presence of gp140-specific IgG and IgA antibody secreting
cells (ASC). Cells from genital tract were assessed immediately
after isolation, whereas the splenocytes were cultured for 72 h at
106 cells/ml in the presence of 20 mg/ml IL-2 (R&D Systems) and
10 mg/ml pokeweed mitogen (Sigma-Aldrich). ELISPOT assays
were performed using a commercial kit from MABTECH (Nacka
Strand, Sweden) following the manufacturer’s recommendations.
The spots were counted using the AID ELISPOT reader ELR03
(Autoimmune Diagnostika).
Cell Proliferation Assay
[3H] Thymidine incorporation. Splenocytes (26105 cells)
were cultured for 5 days with or without 5 mg/ml gp140 in CM
and 5 mg/ml Con-A from Canavalia ensiformis used as a positive
control. Supernatants were collected at 48 h for assessment of
cytokine release by Luminex (R&D). Cells were pulsed with
0.5 mCi [3H]Td/well 18 h before harvesting, and c.p.m. de-
termined in a liquid scintillation b counter (1450 Microbeta Plus,
Wallac Oy). Proliferation response was expressed as stimulation
index (SI), calculated by dividing the c.p.m. of the experimental by
the c.p.m. of the non-stimulated cells (medium alone).
Detection of Cytokines by Multiplex Assay (Luminex)
Mouse IL-4, IL-17, and IFN-c in cell culture supernatants were
detected using a multiplex assay Luminex kit, following the
manufacturer’s protocol (R&D).
Flow Cytometry
All flow cytometry reagents were from BD unless otherwise
stated. For both CFSE and intracellular staining, fifty thousand
events per sample were acquired on a BD FACSCanto II and
analyzed using the BD FACSDiva software version 6.1.3.
Background fluorescence and color compensation was performed
using Anti-Rat Ig beads (BD CompBeads) as described by the
manufacturer. Analysis was performed on the CD3+ T-cell
population by gating on live cells detected by Forward and Side
scatter. Subgating for CD4+ and CD8+ cells from the CD3+ gate
was subsequently performed and expressed as a function of CFSE
staining on the green channel, for proliferation analysis, or as
a function of cytokine-specific fluorochrome-antibody labeled for
cytokine analysis.
CFSE Assay
Splenocytes were stained with 2 mM CFSE for 10 min at 37uC.
The cells were then cultured for 5 days with or without 5 mg/ml
gp140 in CM. Con-A was used at 5 mg/ml as a positive control of
stimulation. Cells were immunostained with 1 mg/ml per million
cells of labeled rat anti-mouse PE-Cy7-CD3, allophycocyanin
(APC) H7-CD8, and APC-CD4. The cells were then stained with
violet fluorescent reactive dye (Live/dead fixable dead cell stain
kit, Invitrogen, Paisley, UK) to separate live from dead cells by
flow cytometry. The proportion of cells per proliferation cycle in
relation to the whole number of gated CD4+ or CD8+ was
calculated and plotted comparatively.
Intracellular Cytokine Staining
Cells were stimulated for 6 hours with a CN54 peptide pool plus
2 mg/ml CD28 in the presence of GolgiStop. Cells cultured in
medium alone or with 50 ng/ml PMA plus 500 ng ionomycin
were used as negative and positive control of stimulation,
respectively. Peptides were selected from a bigger pool of 156
peptides covering the whole of HIV-1 CN54 gp140 for their ability
to restimulate splenocytes in vitro after immunization. Cells were
labeled for mouse surface antigens using Pacific Blue anti CD3e
(BD), V500 anti- CD4 (BD), PerCP anti- CD8a (BioLegend), and
blocked using purified rat anti-mouse CD16/CD32 (BD). After
staining, cells were washed, fixed and permeabilised using BD
Fixation/Permeabilisation Kit. Intracellular cytokine staining was
accomplished using PE-Cy7 anti-mouse IL-4, PE anti-mouse IL-
17A, allophycocyanin-Cy7 anti-mouse IL-2, FITC anti-mouse
TNF-a and allophycocyanin anti-mouse IFNc (All BD). Appro-
priate isotype controls were used in all steps.
Statistical Analyses
Analyses were performed using GraphPad Prism, version 4.00
(GraphPad Software). Data was expressed as the mean 6 SEM.
Statistical differences between 3 or more groups were calculated
by one-way ANOVA with Tukey’s multiple comparison posttest to
compare groups by pairs, or Dunn’s multiple comparison test
when analyzing non-parametric data. Differences between groups
in relation to time were analyzed by two-way ANOVA, with
Bonferroni’s posttest for comparison of pairs. Unpaired Student’s t
test was used to compare the means of two groups. Differences
were considered significant at p#0.05.
Results
Different Formulations of GLA Enhance Humoral Immune
Responses to gp140
Initial experiments were performed to determine whether
a micellar formulation of GLA (GLA-AF) could enhance serum
IgG responses to gp140 that were comparable to those promoted
by the emulsified form (GLA-SE) via the intramuscular route. In
addition, intranasal (i.n.) immunization was compared to in-
tramuscular (i.m.) immunization, because the induction of mucosal
immune responses to gp140 are highly relevant to the de-
velopment of a protective HIV vaccine. GLA-SE was not assessed
for i.n. immunization as emulsions are likely to be less compatible
for i.n. use. Animals were immunized two times at 3 week
intervals, and sampled before (d20) and after (d40) boosting
immunization to test for specific IgG production. The addition of
GLA significantly increased antibody responses compared to
antigen alone, regardless of route or formulation (p,0.001, Fig 1A,
B). After priming, intranasal immunization with GLA-AF i.n.
induced significantly higher IgG titers than antigen alone
(p,0.001, Fig 1A), but lower than the i.m. route. However after
boosting the titer was indistinguishable to the i.m. route (Fig 1B).
By the i.m. route GLA-AF was indistinguishable from GLA-SE
after priming (Fig 1A) or boosting (Fig 1B). A balanced Th1/Th2
response was observed regardless of the route of immunization,
based on levels of IgG1 and IgG2c (Fig 1C). The adjuvant effect of
GLA-AF was derived from the GLA and not the excipients in the
micellar formulation, as immunization with gp140 plus formula-
tion alone had no effect on antibody titer (data not depicted). Both
i.m and i.n immunization with gp140 plus GLA-AF induced
homing to the bone marrow of gp140-IgG-specific long-lived
memory B-cells (Fig 1D). From these studies we conclude that the
micellar formulation of GLA (GLA-AF) is as effective an adjuvant
as the emulsion (GLA-SE) in this model and can be used
intranasally to induce an immune response.
The use of GLA as an Adjuvant Induces Stronger Humoral
Responses than Chitosan or R848
A core aim of our studies was to induce mucosal responses to
HIV and since we observed that i.n. immunization could induce
GLA as a Mucosal Adjuvant for an HIV Antigen
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serum antibody, we wished to test the effect of administration of
GLA-AF by this route on mucosal responses. The adjuvant effect
of GLA was compared with another TLR ligand, R848, which
binds TLR7 in mice (and TLR7/8 in humans), and the
polycationic polysaccharide chitosan, a recognized muco-adherent
product used in the intranasal delivery of vaccines [33]. To allow
comparison with our previous studies using gp140, particularly T
cell protocols [34], these studies were performed in BALB/c mice.
Serum IgG levels in BALB/c mice following i.n. prime/boost
immunization were similar on day 42 (Fig 2A) compared to
C57Bl/6. Animals were immunized three times at 3 week
intervals, and sampled before priming and 3 weeks after every
immunization to test for the magnitude and kinetics of specific IgG
and IgA production in serum, vaginal lavage and feces.
Intranasal immunization with gp140 plus GLA, R848 or
chitosan induced significantly higher titers of IgG in the serum
than antigen alone from d21 (p,0.001, Fig 2A). GLA induced IgG
more rapidly and to a significantly greater level than R848 and
chitosan (p,0.001) on d21, but by d42 IgG levels in sera were
similar in all three groups. It is of note that significant IgG
responses were observed after a single dose of GLA-gp140 (d21).
All three adjuvants induced higher sera IgA levels than antigen
alone by d63. There was no difference between GLA and chitosan
and the responses to both these adjuvants began earlier and
peaked higher than R848. GLA induced significantly higher levels
of IgA than R848 (p,0.001, Fig 2B) following both the first (d42)
and second boost (d63).
All three adjuvants led to detectable antibody responses at
mucosal surfaces. GLA induced significantly higher levels of IgG
(p,0.05, Fig 2C) in the vaginal lavage than either chitosan or
R848 on day 63; and chitosan induced a higher level of
mucosal IgG than R848 at d42 (p,0.001) and d63 (p,0.05).
GLA induced significantly greater levels of vaginal lavage IgA
than R848 at all time points (p,0.01, Fig 2D) and chitosan on
d21 (p,0.05) but not subsequent time points and chitosan
induced higher responses than R848 at d42 and d63 (p,0.01).
A similar, but reduced pattern was seen in the feces (Fig 2E and
2F). While specific IgG titers in feces following GLA-gp140
immunization steadily increased over time, titers induced by
chitosan-gp140 or R848-gp140 decreased after the second
immunization (Fig 2E). Specific IgA was detected in feces after
GLA-gp140 and chitosan-gp140 but not R848-gp140 immuni-
zation (Fig 2F). Specific IgG and IgA responses were also
assessed in nasal lavage at the end of the experiment; GLA,
R848, and chitosan all promoted gp140-specific IgG and IgA
responses (Fig 2G and H). In line with the other mucosal sites,
GLA promoted higher IgG and IgA responses to gp140 than
chitosan, which in turn promoted higher responses than R848.
These results suggest that GLA strongly promotes gp140-specific
IgG and IgA responses both in the systemic and mucosal
Figure 1. Micellar GLA is a potent adjuvant for HIV gp140. C57Bl/6 mice were immunized with 10 mg HIV gp140 antigen alone or in the
presence of different formulations of GLA by the intramuscular (i.m.) or intranasal (i.n.) routes. Micellar GLA (GLA-AF) was given i.m. (D) or i.n. (m) and
emulsion GLA (GLA-SE:N) was given i.m., responses were compared to gp140 alone i.n. (&). Anti-gp140 IgG was measured in sera of mice after prime
(A) or boost (B) immunization. HIV gp140 specific IgG subtypes (C) and bone marrow long-lived plasma cells (D) were measured after 2
immunizations. Bars represent mean of n = 6 mice 6 SEM, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0041144.g001
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compartments following intranasal immunization and that it is
induced more rapidly (single-immunization) and sustained longer
than chitosan or R848.
GLA Promotes gp140-specific IgG and IgA ASC in Spleen
and Genital Tract after Intranasal Immunization
Since GLA and chitosan promoted stronger anti-gp140
responses than R848 we decided to further investigate the nature
of the responses to these adjuvant regimes. B-cell ELISPOT assays
were performed to determine specific IgG and IgA antibody-
secreting cells (ASC) in the spleen and genital tract after i.n.
immunization with gp140. Splenocytes were stimulated for 3 days
with IL-2 plus pokeweed mitogen to increase the likelihood of
detecting specific ASC. To normalize the numbers of specific IgG
and IgA ASC for each treatment, total IgG and IgA ASC were
assessed in parallel. Intranasal gp140 plus GLA induced signifi-
cantly higher numbers of gp140-specific IgA (p,0.001, Fig 3A)
and IgG (p,0.05, Fig 3B) ASC in the spleen than gp140 alone.
These differences were clearly detected before and after normal-
ization against total IgA ASC (data not depicted). Female genital
tracts were collected and pooled (due to low cellular yields) from
mice, following isolation by collagenase digestion and density
gradient purification of lymphocytes. Cells from genital tract were
assessed by ELISPOT for specific gp140 IgG and IgA secretion
immediately after isolation. Intranasal GLA-gp140 induced higher
numbers of gp140-specific IgA ASC in the genital tract than
antigen alone or antigen plus chitosan (Fig 3C), but numbers of
gp140-specific IgG ASC were similar between groups (Fig 3D).
These results show that GLA can promote the induction of high
numbers of gp140-specific IgG and IgA ASC both in spleen and
genital tract after intranasal immunization with gp140.
T Cell Responses Following the use of GLA or Chitosan as
Adjuvants
The ability of GLA and chitosan to enhance T-cell responses to
gp140 following i.n. immunization was assessed. Intranasal
immunization with gp140 and GLA or chitosan induced very
strong antigen specific proliferation responses when compared to
gp140 alone. No differences were observed between the effect of
GLA and chitosan on gp140 specific T-cell proliferative re-
sponsiveness (Fig 4A). To determine the predominant proliferating
T-cell type, a CFSE dilution assay was used. The use of GLA led
to a greater gp140 specific CD4+ T-cell response (p,0.001), in
contrast to a balanced CD4+ and CD8+ T-cell proliferation
response to gp140 when chitosan was used as an adjuvant (Fig 4B).
Comparing the two adjuvants, gp140 specific CD4 responses were
significantly greater after GLA-gp140 than chitosan-gp140
(p,0.01), but CD8 responses were broadly similar. These results
show that i.n. gp140 delivered with both GLA and chitosan
enhance T-cell proliferation, with GLA leading to a stronger CD4
T cell response.
We wished to determine whether the difference in CD4
proliferation was caused by a difference in the quality of T helper
responses. Whilst GLA gave a balanced response, the use of
chitosan significantly biased the antibody response towards IgG1,
indicating a Th2 bias (p,0.001, Fig 4C). To investigate the
differences in cellular responses, the cytokines IL-4, IFNc, and IL-
17 were assessed by a multiplex assay on the cell culture
supernatants obtained from the T-cell proliferation experiments.
Levels of both IL-17 (p,0.001, Fig 4D) and IFNc (p,0.05, Fig 4E)
were significantly higher following the use of GLA as an adjuvant.
The use of chitosan as an adjuvant led to significantly higher levels
of IL-4 than antigen alone (p,0.05, Fig 4F). In parallel,
splenocytes were stimulated with a gp140 peptide pool and the
intracellular expression of the cytokines IFNc, IL-4, TNF and IL-
17 by CD4+ T cells assessed by flow cytometry (Fig 4G). Following
immunization with GLA, significantly more IL-17+ (p,0.01) and
Figure 2. GLA is a more potent mucosal adjuvant than R848 or
chitosan. BALB/c mice were immunized i.n. three times at 3 week
intervals with 10 mg gp140 and 10 mg GLA (m), 10 mg R848 (#) or
100 mg chitosan (%) compared to antigen alone (&). Serum (A, B),
vaginal lavage (C, D), feces (E,F) were collected after each immunization
and nasal lavage collected at d 63 only (G, H). gp140 specific IgG (A, C, E,
G) and IgA (B, D, F, H) were measured by ELISA. Points represent mean
of n= 10 mice 6 SEM, *p,0.05, **p,0.01, ***p,0.001 comparing GLA
and chitosan; #p,0.05, ##p,0.01, ###p,0.001 comparing GLA
and R848.
doi:10.1371/journal.pone.0041144.g002
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TNF+ (p,0.01) CD4+ T cells were detected and immunization
with chitosan significantly increased the proportion of IL-4
secreting CD4 T cells (p,0.01). Of note, Th17 cells were only
induced following i.n. but not i.m. immunization with GLA (data
not depicted). Levels of IFNc-producing CD4T cells were similar
following both regimes and significantly greater than antigen
alone.
Discussion
Here we show that a formulated, synthetic TLR4-based
adjuvant, GLA-AF can be used to boost vaccine responses to
nasally delivered antigens. GLA appears to be more potent than
chitosan or R848, inducing antibody responses that appear earlier
and are of a greater magnitude. Both GLA and chitosan were able
to induce specific antibody and B cell responses at distant mucosal
sites following intranasal immunization. In addition to boosting
antibody responses, both GLA and chitosan boosted T cell
responses, with GLA skewing responses to a Th17 type response
and chitosan skewing responses to Th2.
This is the first study to show that GLA is an effective adjuvant
when delivered mucosally. When used as a parenteral adjuvant,
formulations of GLA have been shown to generate strong immune
responses to influenza [31,35], malaria [23], HIV [36] and TB
[37,38] antigens in mice, with no obvious detrimental side effects.
In the current study GLA induces a slightly more potent antibody
response than chitosan and a greatly more potent response than
the R848 formulation used in this study. In part, this may be
a feature of murine TLR biology and although mice respond to
R848 through TLR7, they do not express functional TLR8.
GLA administration upregulates the expression of CD86 and
CD40 on DC and induces IL-12p70 [36], with a similar
immunostimulatory profile to formulations of the naturally derived
TLR4 ligand MPLA, although with greater potency [27]. The
commercial adjuvant, AS04, contains alum and MPLA and it has
been demonstrated that the adjuvant effect of AS04 is principally
due to the MPLA component [39]. It has also been observed that
the addition of GLA to an oil in water adjuvant was critical for
protective responses [40]. The formulation of the adjuvant is
Figure 3. GLA boosts gp140 specific B cell numbers in spleen
and female genital tract. Mice were immunized i.n. three times at 3
week intervals with 10 mg gp140 alone, with 10 mg GLA or 100 mg
chitosan. Three weeks after the third immunization spleens were
removed and gp140 specific IgA (A) and IgG (B) antibody secreting cell
(ASC) numbers assessed by ELISPOT on splenocytes stimulated for 3
days with IL-2 plus pokeweed mitogen. Bars represent mean of n = 5
mice 6 SEM, *p,0.05, **p,0.01, ***p,0.001. gp140 specific IgA (C)
and IgG (D) antibody secreting cell (ASC) numbers assessed by ELISPOT
on cells from female genital tract immediately after isolation. Bars
represent mean of 2 pools of female genital tract cells, cells were
pooled from either 2 or 3 mice.
doi:10.1371/journal.pone.0041144.g003
Figure 4. GLA boosts T cell responses and switches to a Th17
response. Mice were immunized 3 times with 10 mg gp140 alone or
with 10 mg GLA or 100 mg chitosan. T cell proliferation responses in
spleens were measured by [3H] Thymidine incorporation (A) or CFSE
dilution (B) after the third immunization. Antigen specific IgG subtype
responses were measured in sera (C). IL-17 (D), IFNc (E) and IL-4 (F) were
analyzed in supernatants from T cell proliferation assays by Luminex.
Antigen specific T cell cytokine responses were measured by
intracellular staining of gp140-peptide stimulated T cells (G). Bars
represent mean of n = 5 mice 6 SEM, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0041144.g004
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important, the addition of alum to the AS04 adjuvant may serve to
prolong responses and previous studies have shown that T cell
responses were higher when GLA was formulated in an emulsion
compared to the micellar form and delivered intradermally [41],
however here we show that for HIV gp140, the micellar
formulation gives equivalent responses and can be delivered
intranasally.
In a similar fashion to GLA, high levels of HIV-1 gp140 specific
IgA and IgG were detected in serum, vaginal lavage, and feces,
when chitosan was used as an adjuvant. Chitosan has been shown
to be an effective adjuvant when delivered nasally with influenza
antigens [42], but the mechanism is not known. The adjuvant
effect of chitosan seen here may be due to the opening of epithelial
tight junctions, increasing permeability of the nasal mucosa thus
enhancing diffusion of HIV gp140 into the submucosal compart-
ment [43]. Alternatively, the viscosity of the chitosan may help to
keep the antigen at the epithelial surface for a longer time,
avoiding inhalation into the lungs or swallowing. It has also been
suggested that chitosan can enhance immune responses by
activating natural killer cells, macrophages, and DC [44]. To test
its effect on pattern recognition receptors, we have screened
chitosan against a panel of TLR and NLR cells and have found
that it has no reactivity (data not depicted) suggesting that it works
by increasing epithelial permeability or by acting as an antigen
depot due to its particulate nature.
In contrast to the antibody responses, we saw differences in the
T cell response following the administration of different adjuvants.
The use of GLA induced a greater CD4 T cell proliferation than
chitosan and the response after intranasal GLA was pro-
inflammatory (TNF) and Th17 skewed, whilst chitosan induced
a more Th2 phenotype. When applied to human monocyte-
derived DC, GLA has been shown to induce the upregulation of
IL-6 [27], which may explain the Th17 switch observed in the
current study. Likewise, house dust mite allergen induces a TLR4
dependent pro-Th17 phenotype in lung DCs, upregulating IL-6
and IL-23 [45]. It is not clear why this switch to Th17 only
occurred following i.n. but not i.m. immunization - previous
studies have shown that intramuscular delivery of GLA drives
a Th1 skewing- but the context of antigen exposure often shapes
cellular responses. As described above, chitosan’s mechanism of
action is not known but it is of note that the T cell response is more
Th2 skewed. The Th2 skewing may be associated with its
particulate nature: other microparticles such as alum are also pro-
Th2 [16] and other studies have demonstrated that changing
particle size [46] or route of immunization [34] can change the T
helper bias of responses. It remains to be seen what effect T helper
skewing has on the protective efficacy of an HIV vaccine and it is
of note that the GLA induced TNF and IL-17 producing CD4 T
cells which may promote HIV replication. We have previously
described the use of the pro-Th2 cytokine, TSLP, as a nasal
adjuvant [32] and hypothesized that the absence of pro-
inflammatory T cells at mucosal sites may be advantageous as
they can act as targets for HIV infection.
Here we show that the TLR4 agonist GLA is a potent adjuvant
when delivered intranasally. It is striking that it has a pro-Th17
effect when delivered by this route. Emerging evidence suggests
that Th-17 cells are critical regulators of host defense against
bacterial, fungal, and viral infections at mucosal surfaces as well as
having critical roles in inflammation and autoimmunity [47]. The
role of Th17 responses in immunity to mucosal acquired HIV-1
infection is unclear, however progressive HIV disease is associated
with preferential depletion of CD4 Th17 cells [48–50]. Taken
together, our data show that GLA-AF is a highly potent intranasal
adjuvant greatly enhancing humoral and cellular immune
responses to HIV gp140 both systemically and mucosally. It will
be important to determine the adjuvanticity of GLA for gp140
when delivered intranasally to NHP or humans.
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